Clinical Trial Update: Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating radium-223 dichloride in Asian patients with prostate cancer and bone metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastasis
• Prostate Cancer

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Prostatic Neoplasms | Phase 3 | Status: COMPLETED